Aion Therapeutic Inc.

Recent News

  • Aion Therapeutic Names James W.G. Thompson, Ph.D. as President

    Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. Thompson, Ph.D. as its new president.Dr. Thompson is an accomplished neuroscientist and healthcare technology entrepreneur with over 20 years industry experience. Most recently he co-founded Evoke Neuroscience, Inc., a healthcare technology company founded in 2009 and focused on aiding diagnosis and therapy for neurological disorders. Dr. Thompson served on the Board...

    2020-10-21 9:15 AM ET
  • Aion Therapeutic Announces Closing of Non-Brokered Private Placement

    Toronto, Ontario--(Newsfile Corp. - September 18, 2020) -  Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 9,090,907 units ("Units") at a price of $0.055 per Unit for gross proceeds of approximately $500,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.Each Unit is comprised of one common share ("Common Share") of the Company and one-half of one...

    2020-09-18 5:15 PM ET
  • Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

    Toronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years.He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for most every commercial serum cancer marker currently in use in the United States. Dr. Fritsche...

    2020-09-10 9:00 AM ET
  • Aion Therapeutic Files Five Patents with the United States Patent and Trademark Office

    Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has filed five patent applications with the United States Patent and Trademark Office (USPTO) pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their medicinal properties. These patent applications have formulation claims directed to methods of treating numerous conditions including...

    2020-09-03 9:00 AM ET
  • Aion Therapeutic's Dr. Stephen D. Barnhill to Present at Microdose "Psychedelic Capital Series" on September 3, 2020

    Toronto, Ontario--(Newsfile Corp. - August 31, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion" or the "Company") is pleased to announce that Dr. Stephen D. Barnhill, Executive Chair of the Board, will present live during the Microdose "Psychedelic Capital Series" on Thursday, September 3, 2020 at 1:15 P.M. Eastern Time.The Psychedelic Capital Series is an investor conference series diving deep into psychedelic medicine investment. Each month, Microdose presents a curated group of CEOs, capital advisors, and investment luminaries from around...

    2020-08-31 5:16 PM ET
  • Osoyoos Announces Name Change to "Aion Therapeutic Inc."

    Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that it will be changing its name to "Aion Therapeutic Inc." The Company's new stock symbol on the Canadian Securities Exchange will be "AION", and the name change will be effective on or about August 28, 2020. The Company expects there to be no impact or delays in trading."We are pleased to see our name and ticker symbol change...

    2020-08-27 9:00 AM ET
  • Osoyoos Provides Board Update; Approves Name Change

    Toronto, Ontario--(Newsfile Corp. - August 19, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to provide a Board of Directors ("Board of Directors" or the "Board") update following the recent election of the Company's new Board of Directors which includes the appointment of a new Executive Chair, Executive Vice Chair, Lead Independent Director, composition of all Board committees and Board approval of a corporate name change to Aion Therapeutic Inc.New Board Appointments and Committee CompositionsThe...

    2020-08-19 9:00 AM ET
  • Osoyoos Retains Integrity Media for Investor Relations and Corporate Communications

    Toronto, Ontario--(Newsfile Corp. - August 12, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that the Company has retained Integrity Media Inc. ("Integrity Media") to manage the Company's Investor Relations and Corporate Communications.Integrity Media has over two decades working in public markets and is highly experienced with cannabis and psychedelic-based public companies in the U.S., Canada, the Caribbean and South America. Integrity Media is led by Kurt Divich, a veteran author and public...

    2020-08-12 8:00 AM ET